

# Entela Bollano

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8780113/publications.pdf>

Version: 2024-02-01

37  
papers

606  
citations

687220

13  
h-index

642610

23  
g-index

39  
all docs

39  
docs citations

39  
times ranked

738  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Growth Hormone Secretagogue Hexarelin Improves Cardiac Function in Rats after Experimental Myocardial Infarction. <i>Endocrinology</i> , 2000, 141, 60-66.	1.4	89
2	Impairment of Cardiac Function and Bioenergetics in Adult Transgenic Mice Overexpressing the Bovine Growth Hormone Gene*. <i>Endocrinology</i> , 2000, 141, 2229-2235.	1.4	55
3	Growth Hormone Improves Bioenergetics and Decreases Catecholamines in Postinfarct Rat Hearts**The study was supported by grants from the Swedish Heart and Lung Foundation, the Swedish Medical Research Council, Gothenburg Medical Society, and the Medical Faculty at Gothenburg University.. <i>Endocrinology</i> , 2000, 141, 4592-4599.	1.4	48
4	Induction of Cardiomyopathy in Severe Combined Immunodeficiency Mice by Transfer of Lymphocytes from Patients with Idiopathic Dilated Cardiomyopathy. <i>Autoimmunity</i> , 2000, 32, 271-280.	1.2	45
5	Cardiac remodeling rather than disturbed myocardial energy metabolism is associated with cardiac dysfunction in diabetic rats. <i>International Journal of Cardiology</i> , 2007, 114, 195-201.	0.8	35
6	Cardiovascular Magnetic Resonance in Myocarditis. <i>Diagnostics</i> , 2022, 12, 399.	1.3	27
7	Optimizing the Management of Heart Failure With Preserved Ejection Fraction in the Elderly by Targeting Comorbidities (OPTIMIZE-HFPEF). <i>Journal of Cardiac Failure</i> , 2016, 22, 539-544.	0.7	25
8	Parvovirus B19 in Endomyocardial Biopsy of Patients With Idiopathic Dilated Cardiomyopathy: Foe or Bystander?. <i>Journal of Cardiac Failure</i> , 2019, 25, 60-63.	0.7	21
9	Trends in myocarditis incidence, complications and mortality in Sweden from 2000 to 2014. <i>Scientific Reports</i> , 2022, 12, 1810.	1.6	20
10	Prognostic impact over time of ischaemic heart disease vs. non-ischaemic heart disease in heart failure. <i>ESC Heart Failure</i> , 2020, 7, 265-274.	1.4	16
11	Diagnosis, management, and outcome of cardiac sarcoidosis and giant cell myocarditis: a Swedish single center experience. <i>BMC Cardiovascular Disorders</i> , 2022, 22, 192.	0.7	16
12	Continuous improvement in outcome after heart transplantation – Long-term follow-up after three decades of experience. <i>International Journal of Cardiology</i> , 2017, 231, 188-194.	0.8	15
13	Short- and long-term outcomes after heart transplantation in cardiac sarcoidosis and giant-cell myocarditis: a systematic review and meta-analysis. <i>Clinical Research in Cardiology</i> , 2022, 111, 125-140.	1.5	15
14	Glucosylceramide synthase deficiency in the heart compromises $\beta$ 1-adrenergic receptor trafficking. <i>European Heart Journal</i> , 2021, 42, 4481-4492.	1.0	14
15	Growth Hormone Improves Bioenergetics and Decreases Catecholamines in Postinfarct Rat Hearts. <i>Endocrinology</i> , 2000, 141, 4592-4599.	1.4	14
16	Grading right ventricular dysfunction in left ventricular disease using echocardiography: a proof of concept using a novel multiparameter strategy. <i>ESC Heart Failure</i> , 2021, 8, 3223-3236.	1.4	11
17	Cardiac arrest in Wilson's disease after curative liver transplantation: a life-threatening complication of myocardial copper excess?. <i>ESC Heart Failure</i> , 2019, 6, 228-231.	1.4	10
18	Exercise-based cardiac rehabilitation improves physical fitness in patients with permanent atrial fibrillation – A randomized controlled study. <i>Translational Sports Medicine</i> , 2020, 3, 415-425.	0.5	10

#	ARTICLE	IF	CITATIONS
19	Risk of stroke in patients with heart failure and sinus rhythm: data from the Swedish Heart Failure Registry. <i>ESC Heart Failure</i> , 2021, 8, 85-94.	1.4	9
20	Growth hormone alone or combined with metoprolol preserves cardiac function after myocardial infarction in rats. <i>European Journal of Heart Failure</i> , 2001, 3, 651-660.	2.9	8
21	Temporal trends in characteristics and outcome of heart failure patients with and without significant coronary artery disease. <i>ESC Heart Failure</i> , 2022, 9, 1812-1822.	1.4	8
22	Real-world treatment patterns, resource use and costs of treating uncontrolled carcinoid syndrome and carcinoid heart disease: a retrospective Swedish study. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 1509-1518.	0.6	7
23	Temporal trends in outcome and patient characteristics in dilated cardiomyopathy, data from the Swedish Heart Failure Registry 2003-2015. <i>BMC Cardiovascular Disorders</i> , 2021, 21, 307.	0.7	7
24	How should we manage early tricuspid valve regurgitation after heart transplantation?. <i>International Journal of Cardiology</i> , 2016, 214, 191-193.	0.8	6
25	Stress echocardiography using transesophageal atrial pacing in rats. <i>Journal of the American Society of Echocardiography</i> , 2003, 16, 326-332.	1.2	5
26	Somatostatin Receptor Positron Emission Tomography/Computed Tomography in Giant Cell Myocarditis: A Promising Approach to Molecular Myocardial Inflammation Imaging. <i>Circulation: Cardiovascular Imaging</i> , 2022, 15, CIRCIMAGING121013551.	1.3	5
27	Somatostatin receptor PET/CT in myocarditis following mRNA COVID-19 vaccination. <i>European Heart Journal - Case Reports</i> , 2022, 6, ytac117.	0.3	4
28	Phenotypic and HLA-DRB1 allele characterization of Swedish cardiac sarcoidosis patients. <i>International Journal of Cardiology</i> , 2022, , .	0.8	4
29	Early post-transplant elevated pulmonary artery pressure predicts adverse outcome in cardiac recipients. <i>IJC Heart and Vasculature</i> , 2020, 26, 100438.	0.6	3
30	Inflammatory cardiomyopathies: short- and long-term outcomes after heart transplantation—a protocol for a systematic review and meta-analysis. <i>Heart Failure Reviews</i> , 2020, 25, 481-485.	1.7	3
31	Association between central haemodynamics and renal function in advanced heart failure: a nationwide study from Sweden. <i>ESC Heart Failure</i> , 2022, 9, 2654-2663.	1.4	3
32	Invasive haemodynamics in de novo everolimus vs. calcineurin inhibitor heart transplant recipients. <i>ESC Heart Failure</i> , 2020, 7, 567-576.	1.4	2
33	Incidental cardiac findings on somatostatin receptor PET/CT: What do they indicate and are they of clinical relevance?. <i>Journal of Nuclear Cardiology</i> , 2022, 29, 1159-1165.	1.4	2
34	Prognostic differences in long-standing vs. recent-onset dilated cardiomyopathy. <i>ESC Heart Failure</i> , 2022, , .	1.4	2
35	A Retrospective Study of Posttransplant Amiodarone Exposition on Clad Development and Survival After Lung Transplantation. <i>Transplantation Proceedings</i> , 2022, 54, 789-794.	0.3	2
36	Cardiac involvement in immune-mediated necrotizing myopathy: insights from CMR and somatostatin receptor PET/CT. <i>European Heart Journal Cardiovascular Imaging</i> , 2022, 23, e237-e237.	0.5	2

#	ARTICLE	IF	CITATIONS
37	Effect of growth hormone treatment on circulating levels of NT-proBNP in patients with ischemic heart failure. Growth Hormone and IGF Research, 2020, 55, 101359.	0.5	1